Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7
A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After...
Gespeichert in:
Veröffentlicht in: | Annals of hematology 1996-05, Vol.72 (5), p.337-340 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 340 |
---|---|
container_issue | 5 |
container_start_page | 337 |
container_title | Annals of hematology |
container_volume | 72 |
creator | HASHINO, S IMAMURA, M TANAKA, J KOBAYASHI, S MUSASHI, M KASAI, M ASAKA, M |
description | A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After 2 years of the therapy, monosomy 7 was detected during cytogenetic analysis of his bone marrow, which evolved during a period of 5 months into acute myeloblastic leukemia. An in vitro proliferation assay of cytokine responses showed that leukemic blasts were sensitive only to G-CSF, and not to EPO or IL-6. Although allogeneic bone marrow transplantation from an HLA-matched unrelated donor was carried out in the non-remission stage, the patient died of systemic fungal infection on day 25, without any evidence of hematological engraftment. As long-term use of cytokines and immunomo-suppressants in patients with severe aplastic anemia may induce or hasten the onset of a malignant transformation, careful attention must be paid to clonal evolution. Due to the poor prognosis of secondary myelodysplasia and leukemia, allogeneic bone marrow transplantation for such patients must be carried out early in the course of the disease. |
doi_str_mv | 10.1007/s002770050183 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78088232</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78088232</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-6bdc262e69e89f2a3613be8a3494f27dac31fe76d43bb451be2e075345bb5833</originalsourceid><addsrcrecordid>eNpVkEtLxDAUhYMo4zi6dClkIe6qeTbpUsQXDLiZjauSZG4x2jRj0irz761OGfBuzuJ8HC4fQueUXFNC1E0mhClFiCRU8wM0p4KzgkgtDtGcVLwq5HjH6CTnd0Io04LN0EyXQipRzdHrKpkuNzEF0_vY4djgDF-QAJtNa3LvHTYdBG-w7_qIjRt6wGELbbRT3cLw8Qd8-_4Nh9jFHMMWq1N01Jg2w9mUC7R6uF_dPRXLl8fnu9tl4ThVfVHatWMlg7ICXTXM8JJyC9pwUYmGqbUZsQZUuRbcWiGpBQZESS6ktVJzvkBXu9lNip8D5L4OPjto2_HtOORaaaI142wEix3oUsw5QVNvkg8mbWtK6l-T9T-TI38xDQ82wHpPT-rG_nLqTXambUaPzuc9xkmldSn5D56Je6s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78088232</pqid></control><display><type>article</type><title>Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>HASHINO, S ; IMAMURA, M ; TANAKA, J ; KOBAYASHI, S ; MUSASHI, M ; KASAI, M ; ASAKA, M</creator><creatorcontrib>HASHINO, S ; IMAMURA, M ; TANAKA, J ; KOBAYASHI, S ; MUSASHI, M ; KASAI, M ; ASAKA, M</creatorcontrib><description>A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After 2 years of the therapy, monosomy 7 was detected during cytogenetic analysis of his bone marrow, which evolved during a period of 5 months into acute myeloblastic leukemia. An in vitro proliferation assay of cytokine responses showed that leukemic blasts were sensitive only to G-CSF, and not to EPO or IL-6. Although allogeneic bone marrow transplantation from an HLA-matched unrelated donor was carried out in the non-remission stage, the patient died of systemic fungal infection on day 25, without any evidence of hematological engraftment. As long-term use of cytokines and immunomo-suppressants in patients with severe aplastic anemia may induce or hasten the onset of a malignant transformation, careful attention must be paid to clonal evolution. Due to the poor prognosis of secondary myelodysplasia and leukemia, allogeneic bone marrow transplantation for such patients must be carried out early in the course of the disease.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s002770050183</identifier><identifier>PMID: 8645749</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Anemia, Aplastic - complications ; Anemia, Aplastic - therapy ; Anemias. Hemoglobinopathies ; Antilymphocyte Serum - therapeutic use ; Biological and medical sciences ; Bone Marrow Transplantation ; Chromosomes, Human, Pair 7 ; Cyclosporine - therapeutic use ; Diseases of red blood cells ; Erythropoietin - therapeutic use ; Granulocyte Colony-Stimulating Factor - therapeutic use ; Hematologic and hematopoietic diseases ; Humans ; Interleukin-6 - therapeutic use ; Leukemia, Myeloid, Acute - etiology ; Leukemia, Myeloid, Acute - genetics ; Male ; Medical sciences ; Monosomy</subject><ispartof>Annals of hematology, 1996-05, Vol.72 (5), p.337-340</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c317t-6bdc262e69e89f2a3613be8a3494f27dac31fe76d43bb451be2e075345bb5833</citedby><cites>FETCH-LOGICAL-c317t-6bdc262e69e89f2a3613be8a3494f27dac31fe76d43bb451be2e075345bb5833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3098865$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8645749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HASHINO, S</creatorcontrib><creatorcontrib>IMAMURA, M</creatorcontrib><creatorcontrib>TANAKA, J</creatorcontrib><creatorcontrib>KOBAYASHI, S</creatorcontrib><creatorcontrib>MUSASHI, M</creatorcontrib><creatorcontrib>KASAI, M</creatorcontrib><creatorcontrib>ASAKA, M</creatorcontrib><title>Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After 2 years of the therapy, monosomy 7 was detected during cytogenetic analysis of his bone marrow, which evolved during a period of 5 months into acute myeloblastic leukemia. An in vitro proliferation assay of cytokine responses showed that leukemic blasts were sensitive only to G-CSF, and not to EPO or IL-6. Although allogeneic bone marrow transplantation from an HLA-matched unrelated donor was carried out in the non-remission stage, the patient died of systemic fungal infection on day 25, without any evidence of hematological engraftment. As long-term use of cytokines and immunomo-suppressants in patients with severe aplastic anemia may induce or hasten the onset of a malignant transformation, careful attention must be paid to clonal evolution. Due to the poor prognosis of secondary myelodysplasia and leukemia, allogeneic bone marrow transplantation for such patients must be carried out early in the course of the disease.</description><subject>Adult</subject><subject>Anemia, Aplastic - complications</subject><subject>Anemia, Aplastic - therapy</subject><subject>Anemias. Hemoglobinopathies</subject><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Transplantation</subject><subject>Chromosomes, Human, Pair 7</subject><subject>Cyclosporine - therapeutic use</subject><subject>Diseases of red blood cells</subject><subject>Erythropoietin - therapeutic use</subject><subject>Granulocyte Colony-Stimulating Factor - therapeutic use</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Interleukin-6 - therapeutic use</subject><subject>Leukemia, Myeloid, Acute - etiology</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Monosomy</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkEtLxDAUhYMo4zi6dClkIe6qeTbpUsQXDLiZjauSZG4x2jRj0irz761OGfBuzuJ8HC4fQueUXFNC1E0mhClFiCRU8wM0p4KzgkgtDtGcVLwq5HjH6CTnd0Io04LN0EyXQipRzdHrKpkuNzEF0_vY4djgDF-QAJtNa3LvHTYdBG-w7_qIjRt6wGELbbRT3cLw8Qd8-_4Nh9jFHMMWq1N01Jg2w9mUC7R6uF_dPRXLl8fnu9tl4ThVfVHatWMlg7ICXTXM8JJyC9pwUYmGqbUZsQZUuRbcWiGpBQZESS6ktVJzvkBXu9lNip8D5L4OPjto2_HtOORaaaI142wEix3oUsw5QVNvkg8mbWtK6l-T9T-TI38xDQ82wHpPT-rG_nLqTXambUaPzuc9xkmldSn5D56Je6s</recordid><startdate>19960501</startdate><enddate>19960501</enddate><creator>HASHINO, S</creator><creator>IMAMURA, M</creator><creator>TANAKA, J</creator><creator>KOBAYASHI, S</creator><creator>MUSASHI, M</creator><creator>KASAI, M</creator><creator>ASAKA, M</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960501</creationdate><title>Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7</title><author>HASHINO, S ; IMAMURA, M ; TANAKA, J ; KOBAYASHI, S ; MUSASHI, M ; KASAI, M ; ASAKA, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-6bdc262e69e89f2a3613be8a3494f27dac31fe76d43bb451be2e075345bb5833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Anemia, Aplastic - complications</topic><topic>Anemia, Aplastic - therapy</topic><topic>Anemias. Hemoglobinopathies</topic><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Transplantation</topic><topic>Chromosomes, Human, Pair 7</topic><topic>Cyclosporine - therapeutic use</topic><topic>Diseases of red blood cells</topic><topic>Erythropoietin - therapeutic use</topic><topic>Granulocyte Colony-Stimulating Factor - therapeutic use</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Interleukin-6 - therapeutic use</topic><topic>Leukemia, Myeloid, Acute - etiology</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Monosomy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HASHINO, S</creatorcontrib><creatorcontrib>IMAMURA, M</creatorcontrib><creatorcontrib>TANAKA, J</creatorcontrib><creatorcontrib>KOBAYASHI, S</creatorcontrib><creatorcontrib>MUSASHI, M</creatorcontrib><creatorcontrib>KASAI, M</creatorcontrib><creatorcontrib>ASAKA, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HASHINO, S</au><au>IMAMURA, M</au><au>TANAKA, J</au><au>KOBAYASHI, S</au><au>MUSASHI, M</au><au>KASAI, M</au><au>ASAKA, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7</atitle><jtitle>Annals of hematology</jtitle><addtitle>Ann Hematol</addtitle><date>1996-05-01</date><risdate>1996</risdate><volume>72</volume><issue>5</issue><spage>337</spage><epage>340</epage><pages>337-340</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After 2 years of the therapy, monosomy 7 was detected during cytogenetic analysis of his bone marrow, which evolved during a period of 5 months into acute myeloblastic leukemia. An in vitro proliferation assay of cytokine responses showed that leukemic blasts were sensitive only to G-CSF, and not to EPO or IL-6. Although allogeneic bone marrow transplantation from an HLA-matched unrelated donor was carried out in the non-remission stage, the patient died of systemic fungal infection on day 25, without any evidence of hematological engraftment. As long-term use of cytokines and immunomo-suppressants in patients with severe aplastic anemia may induce or hasten the onset of a malignant transformation, careful attention must be paid to clonal evolution. Due to the poor prognosis of secondary myelodysplasia and leukemia, allogeneic bone marrow transplantation for such patients must be carried out early in the course of the disease.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>8645749</pmid><doi>10.1007/s002770050183</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0939-5555 |
ispartof | Annals of hematology, 1996-05, Vol.72 (5), p.337-340 |
issn | 0939-5555 1432-0584 |
language | eng |
recordid | cdi_proquest_miscellaneous_78088232 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Adult Anemia, Aplastic - complications Anemia, Aplastic - therapy Anemias. Hemoglobinopathies Antilymphocyte Serum - therapeutic use Biological and medical sciences Bone Marrow Transplantation Chromosomes, Human, Pair 7 Cyclosporine - therapeutic use Diseases of red blood cells Erythropoietin - therapeutic use Granulocyte Colony-Stimulating Factor - therapeutic use Hematologic and hematopoietic diseases Humans Interleukin-6 - therapeutic use Leukemia, Myeloid, Acute - etiology Leukemia, Myeloid, Acute - genetics Male Medical sciences Monosomy |
title | Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T13%3A05%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transformation%20of%20severe%20aplastic%20anemia%20into%20acute%20myeloblastic%20leukemia%20with%20monosomy%207&rft.jtitle=Annals%20of%20hematology&rft.au=HASHINO,%20S&rft.date=1996-05-01&rft.volume=72&rft.issue=5&rft.spage=337&rft.epage=340&rft.pages=337-340&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s002770050183&rft_dat=%3Cproquest_cross%3E78088232%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78088232&rft_id=info:pmid/8645749&rfr_iscdi=true |